Esperion Therapeutics, Inc.
Price Action
Technical Summary
EMERGING TRENDEsperion Therapeutics, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings growth of 52% provides fundamental context to the price action. Investors should exercise caution due to high volatility (91% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $3.15 | +0.25% | ABOVE |
| 50 SMA | $2.97 | +6.38% | ABOVE |
| 100 SMA | $2.87 | +9.96% | ABOVE |
| 150 SMA | $3.12 | +1.13% | ABOVE |
| 200 SMA | $3.04 | +3.87% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ESPR in an uptrend right now?
ESPR has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ESPR overbought or oversold?
ESPR's RSI (14) is 64. The stock is in neutral territory, neither overbought nor oversold.
Is ESPR outperforming the market?
ESPR has a Relative Strength (RS) Rating of 78 out of 99. ESPR is performing about average compared to the market.
Where is ESPR in its 52-week range?
ESPR is trading at $3.16, which is 76% of its 52-week high ($4.18) and 67% above its 52-week low ($1.10).
How volatile is ESPR?
ESPR has a Beta of 1.85 and 52-week volatility of 91%. It's more volatile than the S&P 500 - expect bigger swings.